UBS lowered the firm’s price target on Trinity Capital (TRIN) to $17 from $18 and keeps a Buy rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRIN:
- Candel Therapeutics enters into $130M term loan facility
- Trinity Capital provides $130M in growth capital to Candel Therapeutics
- Trinity Capital Announces Q3 2025 Portfolio Activity
- Trinity Capital originates $773M of new commitments in Q3
- Trinity Capital provides $45M in growth capital to Rapid Micro Biosystems